196 related articles for article (PubMed ID: 14674790)
1. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
[TBL] [Abstract][Full Text] [Related]
2. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
3. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Faber MS; Fuhr U
Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
[TBL] [Abstract][Full Text] [Related]
4. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
5. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
7. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U
Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
Thai C; Tayo B; Critchley D
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
10. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians.
Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011
[TBL] [Abstract][Full Text] [Related]
11. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.
Simon T; Becquemont L; Hamon B; Nouyrigat E; Chodjania Y; Poirier JM; Funck-Brentano C; Jaillon P
Br J Clin Pharmacol; 2001 Nov; 52(5):601-4. PubMed ID: 11736870
[TBL] [Abstract][Full Text] [Related]
12. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
13. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Spigset O; Hägg S; Söderström E; Dahlqvist R
Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
[TBL] [Abstract][Full Text] [Related]
15. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
16. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
17. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm.
Kisor DF; Watling SM; Zarowitz BJ; Jelliffe RW
Clin Pharmacokinet; 1992 Jul; 23(1):62-8. PubMed ID: 1617859
[TBL] [Abstract][Full Text] [Related]
19. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239
[TBL] [Abstract][Full Text] [Related]
20. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
